Business Daily Media

Business Marketing

.

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

  • Written by ACN Newswire - Press Releases

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

TOKYO, Jul 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep

Read more //?#

Popular

Three tools that my remote business couldn’t live without

Business owners need to get lots of things done in the most efficient way. In order to get there, it’s critical for business owners to invest in making sure their tech is up-to-date and efficient. There are a handful of apps...

NSW maintains position as Australia’s tech capital

ACS, the association for IT professionals in Australia, today released the ACS Australia’s Digital Pulse 2020 report for New South Wales. Prepared by Deloitte Access Economics, this annual report provides a detailed examinat...

Vulnerable Businesses Underprepared for Another Disaster - New Research

Despite the impacts of COVID, Australian businesses have still not put safeguards in place to ensure their viability in another pandemic or natural disaster.    According to new research a large portion of Australian busin...